A new era in obesity management

2023 was the most memorable year on record for obesity. The American Academy of Pediatrics recognized the complex, multifactorial nature of obesity and the broad range of treatments necessary to care for pediatric patients. The first-ever triple agonist and high-potency oral GLP1 agonist was introduced with unprecedented results. The American Academy of Pediatrics published its first updated clinical practice guideline in 15 years, recognizing the complex, multifactorial nature of paediatric obesity and embracing the full range of treatment modalities, including lifestyle, pharmacotherapy, and metabolic and bariatric surgery4.High-potency GLP1 agonism could only be delivered in injectable form until the oral GLP1 orforglipron study demonstrated similar efficacy to its injectable counterparts5.For the first time, phase II clinical trial results demonstrated that triple-agonist, an agonist of the glucose-dependent insulinotropic polypeptide, GLP1 and glucagon receptors, retatrutide showed higher total body weight loss than any agent prior6.